Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 12 | 2013 | 581 | 2.710 |
Why?
|
| Biomarkers, Tumor | 8 | 2013 | 1555 | 1.130 |
Why?
|
| Diagnosis, Differential | 14 | 2022 | 1600 | 0.880 |
Why?
|
| Neurothekeoma | 2 | 2012 | 5 | 0.800 |
Why?
|
| Chancre | 1 | 2020 | 2 | 0.730 |
Why?
|
| Syphilis, Cutaneous | 1 | 2020 | 3 | 0.730 |
Why?
|
| Treponema pallidum | 1 | 2020 | 8 | 0.730 |
Why?
|
| Skin Diseases | 2 | 2012 | 173 | 0.720 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 68 | 0.710 |
Why?
|
| Rectum | 1 | 2020 | 148 | 0.670 |
Why?
|
| Skin | 2 | 2020 | 583 | 0.660 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 6 | 0.660 |
Why?
|
| Conjunctival Diseases | 1 | 2018 | 7 | 0.640 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 1801 | 0.640 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 22 | 0.640 |
Why?
|
| Hernia | 1 | 2018 | 23 | 0.640 |
Why?
|
| Orbital Diseases | 1 | 2018 | 21 | 0.630 |
Why?
|
| Drug Eruptions | 1 | 2018 | 34 | 0.600 |
Why?
|
| Adipose Tissue | 1 | 2018 | 259 | 0.530 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 202 | 0.510 |
Why?
|
| Sarcoma | 2 | 2007 | 220 | 0.510 |
Why?
|
| Intestinal Mucosa | 1 | 2020 | 805 | 0.510 |
Why?
|
| Receptors, IgE | 1 | 2015 | 7 | 0.510 |
Why?
|
| Penile Neoplasms | 2 | 2022 | 17 | 0.500 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2015 | 44 | 0.500 |
Why?
|
| Urticaria | 1 | 2015 | 14 | 0.500 |
Why?
|
| Histiocytoma, Benign Fibrous | 2 | 2011 | 25 | 0.460 |
Why?
|
| Autoantibodies | 1 | 2015 | 268 | 0.450 |
Why?
|
| Meningioma | 1 | 2013 | 63 | 0.430 |
Why?
|
| Middle Aged | 17 | 2022 | 26044 | 0.420 |
Why?
|
| Handwriting | 1 | 2012 | 6 | 0.420 |
Why?
|
| Medical Audit | 1 | 2012 | 39 | 0.410 |
Why?
|
| Neurofibroma, Plexiform | 1 | 2012 | 10 | 0.410 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 146 | 0.410 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2012 | 14 | 0.410 |
Why?
|
| Aged | 15 | 2022 | 19217 | 0.400 |
Why?
|
| DNA, Viral | 1 | 2012 | 262 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1412 | 0.390 |
Why?
|
| Indoles | 1 | 2013 | 315 | 0.390 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 290 | 0.380 |
Why?
|
| Bowen's Disease | 1 | 2011 | 9 | 0.380 |
Why?
|
| Paget Disease, Extramammary | 1 | 2011 | 8 | 0.380 |
Why?
|
| Lipoma | 1 | 2011 | 27 | 0.380 |
Why?
|
| Alopecia | 2 | 2021 | 34 | 0.370 |
Why?
|
| Sulfonamides | 1 | 2013 | 318 | 0.370 |
Why?
|
| Herpes Simplex | 1 | 2012 | 203 | 0.370 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 260 | 0.370 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 56 | 0.370 |
Why?
|
| Carcinoma in Situ | 1 | 2011 | 53 | 0.360 |
Why?
|
| Male | 18 | 2022 | 42514 | 0.360 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2013 | 1276 | 0.360 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2010 | 17 | 0.360 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2009 | 3 | 0.340 |
Why?
|
| Female | 18 | 2021 | 46328 | 0.340 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 6828 | 0.340 |
Why?
|
| Collagen | 1 | 2011 | 293 | 0.340 |
Why?
|
| Leiomyoma | 1 | 2013 | 202 | 0.340 |
Why?
|
| Humans | 27 | 2022 | 89570 | 0.330 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2010 | 128 | 0.330 |
Why?
|
| Melanoma | 1 | 2013 | 470 | 0.330 |
Why?
|
| Arm | 1 | 2009 | 98 | 0.320 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2010 | 132 | 0.320 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2008 | 2 | 0.320 |
Why?
|
| Glomus Tumor | 1 | 2008 | 9 | 0.310 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 27 | 0.310 |
Why?
|
| Electronic Health Records | 1 | 2012 | 351 | 0.310 |
Why?
|
| Nipples | 1 | 2008 | 37 | 0.310 |
Why?
|
| Leg | 1 | 2008 | 140 | 0.300 |
Why?
|
| Adult | 11 | 2022 | 26676 | 0.290 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2007 | 2 | 0.290 |
Why?
|
| Buttocks | 1 | 2007 | 10 | 0.290 |
Why?
|
| CD56 Antigen | 1 | 2007 | 18 | 0.290 |
Why?
|
| Leiomyosarcoma | 1 | 2007 | 45 | 0.290 |
Why?
|
| Fibroma | 1 | 2007 | 33 | 0.280 |
Why?
|
| CD4 Antigens | 1 | 2007 | 83 | 0.280 |
Why?
|
| Leukemia, Myeloid | 1 | 2008 | 249 | 0.270 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 437 | 0.270 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2006 | 10 | 0.270 |
Why?
|
| Transcription Factors | 1 | 2013 | 1657 | 0.250 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 638 | 0.240 |
Why?
|
| Biopsy | 3 | 2020 | 1185 | 0.240 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 343 | 0.220 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2022 | 4 | 0.210 |
Why?
|
| Vascular Neoplasms | 1 | 2022 | 20 | 0.210 |
Why?
|
| Ustekinumab | 1 | 2021 | 51 | 0.190 |
Why?
|
| Young Adult | 4 | 2022 | 6341 | 0.190 |
Why?
|
| Child | 3 | 2019 | 7190 | 0.160 |
Why?
|
| Illinois | 1 | 2020 | 483 | 0.160 |
Why?
|
| Sampling Studies | 1 | 2018 | 72 | 0.160 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 25 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1201 | 0.160 |
Why?
|
| Lichenoid Eruptions | 1 | 2018 | 3 | 0.160 |
Why?
|
| Psoriasis | 1 | 2021 | 245 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 237 | 0.150 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 233 | 0.150 |
Why?
|
| Granuloma | 1 | 2018 | 65 | 0.150 |
Why?
|
| Prefrontal Cortex | 1 | 2018 | 135 | 0.140 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 922 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 173 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2010 | 541 | 0.130 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 465 | 0.130 |
Why?
|
| Lichen Planus | 1 | 2015 | 10 | 0.130 |
Why?
|
| Glioblastoma | 1 | 2018 | 265 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1727 | 0.130 |
Why?
|
| Scalp | 1 | 2015 | 72 | 0.130 |
Why?
|
| Mast Cells | 1 | 2015 | 94 | 0.120 |
Why?
|
| Actins | 2 | 2008 | 460 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 1774 | 0.120 |
Why?
|
| Eosinophils | 1 | 2015 | 194 | 0.120 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 3015 | 0.120 |
Why?
|
| Neutrophils | 1 | 2015 | 308 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 249 | 0.110 |
Why?
|
| Chickenpox | 1 | 2012 | 38 | 0.100 |
Why?
|
| Adolescent | 3 | 2021 | 9281 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 40 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2013 | 338 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 783 | 0.100 |
Why?
|
| Herpes Zoster | 1 | 2012 | 79 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2013 | 280 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 950 | 0.100 |
Why?
|
| Simplexvirus | 1 | 2012 | 151 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.100 |
Why?
|
| PAX8 Transcription Factor | 1 | 2010 | 23 | 0.090 |
Why?
|
| Paired Box Transcription Factors | 1 | 2010 | 52 | 0.090 |
Why?
|
| Hypersensitivity | 1 | 2012 | 159 | 0.090 |
Why?
|
| Mucin-1 | 1 | 2010 | 45 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 1977 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2010 | 159 | 0.090 |
Why?
|
| Ki-1 Antigen | 1 | 2009 | 19 | 0.080 |
Why?
|
| Extracellular Matrix | 1 | 2011 | 245 | 0.080 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 111 | 0.080 |
Why?
|
| Collagen Type IV | 1 | 2008 | 26 | 0.080 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2008 | 11 | 0.080 |
Why?
|
| Muramidase | 1 | 2008 | 35 | 0.080 |
Why?
|
| Peroxidase | 1 | 2008 | 51 | 0.080 |
Why?
|
| Mitosis | 1 | 2008 | 152 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2008 | 284 | 0.070 |
Why?
|
| Ossification, Heterotopic | 1 | 2007 | 33 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2006 | 21 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2010 | 1115 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2008 | 466 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2008 | 600 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 1217 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2008 | 8266 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2012 | 3740 | 0.060 |
Why?
|
| Prostatic Hyperplasia | 1 | 2006 | 91 | 0.060 |
Why?
|
| Retrospective Studies | 1 | 2018 | 9080 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1527 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2006 | 900 | 0.060 |
Why?
|
| Prostatectomy | 1 | 2006 | 477 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1225 | 0.050 |
Why?
|
| Penis | 1 | 2022 | 60 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 1097 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 1492 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 2017 | 0.050 |
Why?
|
| Pregnancy | 1 | 2008 | 3027 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 2018 | 0.040 |
Why?
|
| Prognosis | 1 | 2007 | 3792 | 0.040 |
Why?
|
| Extremities | 1 | 2015 | 170 | 0.030 |
Why?
|
| Keratins | 1 | 2009 | 63 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2009 | 51 | 0.020 |
Why?
|